Moderna CEO Recalls Birthday Dinner Win That Validates Decade-Long Bet

Moderna CEO Stephane Bancel recalled learning of his company's cancer vaccine trial win at a Lebanese birthday dinner, marking a significant milestone for mRNA medicine. The vaccine, mRNA-4157/V940, developed with US drugmaker Merck, met its primary efficacy endpoint in the Phase 2b KEYNOTE-942 trial, cutting the risk of recurrence or death in patients with high-risk melanoma by 44 percent compared to Keytruda alone.

Bancel was at a Lebanese restaurant celebrating a friend's birthday when he received the news. The moment marked one of the defining turns in Moderna's post-pandemic history and validated Bancel's decade-long bet on mRNA technology.

The trial enrolled 157 patients with resected stage III/IV high-risk melanoma, with 107 receiving the personalized vaccine plus pembrolizumab (Keytruda) and 50 receiving Keytruda alone. The combination showed a statistically significant clinical benefit, convincing Merck to exercise its option on the programme.

The US Food and Drug Administration granted the regimen Breakthrough Therapy Designation in February 2023, accelerating its development path. Moderna manufactures each patient's personalized dose while Merck distributes it alongside Keytruda. The partnership splits profits 50/50 if regulators approve the vaccine.